J
Johannes H. Schulte
Researcher at Charité
Publications - 198
Citations - 11678
Johannes H. Schulte is an academic researcher from Charité. The author has contributed to research in topics: Neuroblastoma & Anaplastic lymphoma kinase. The author has an hindex of 50, co-authored 198 publications receiving 9351 citations. Previous affiliations of Johannes H. Schulte include Humboldt University of Berlin & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
The landscape of genomic alterations across childhood cancers
Susanne Gröbner,Barbara C. Worst,Joachim Weischenfeldt,Joachim Weischenfeldt,Ivo Buchhalter,Kortine Kleinheinz,Vasilisa A. Rudneva,Pascal Johann,Gnana Prakash Balasubramanian,Maia Segura-Wang,Sebastian Brabetz,Sebastian Bender,Barbara Hutter,Dominik Sturm,Elke Pfaff,Daniel Hübschmann,Gideon Zipprich,Michael Heinold,Michael Heinold,Jürgen Eils,Christian Lawerenz,Serap Erkek,Sander Lambo,Sebastian M. Waszak,Claudia Blattmann,Arndt Borkhardt,Arndt Borkhardt,Michaela Kuhlen,Michaela Kuhlen,Angelika Eggert,Angelika Eggert,Simone Fulda,Manfred Gessler,Jenny Wegert,Roland Kappler,Roland Kappler,Daniel Baumhoer,Stefan Burdach,Stefan Burdach,Renate Kirschner-Schwabe,Renate Kirschner-Schwabe,Udo Kontny,Andreas E. Kulozik,Andreas E. Kulozik,Dietmar R. Lohmann,Simone Hettmer,Cornelia Eckert,Cornelia Eckert,Stefan S. Bielack,Michaela Nathrath,Michaela Nathrath,Charlotte M. Niemeyer,Charlotte M. Niemeyer,Gunther Richter,Gunther Richter,Johannes H. Schulte,Johannes H. Schulte,Reiner Siebert,Frank Westermann,Jan J. Molenaar,Gilles Vassal,Hendrik Witt,Peter Lichter,Ursula Weber,Roland Eils,Roland Eils,Andrey Korshunov,Olaf Witt,Stefan Pfister,Guido Reifenberger,J Felsberg,Christof von Kalle,Manfred Schmidt,Cynthia Bartholomä,Michael Taylor,David T. W. Jones,Natalie Jäger,Korbel Jo,Adrian M. Stütz,Tobias Rausch,Bernhard Radlwimmer,Marie-Laure Yaspo,Hans Lehrach,Hans-Jörg Warnatz,Pablo Landgraf,Benedikt Brors,Marc Zapatka,Marc Zapatka,Susanne Wagner,Susanne Wagner,Andrea Haake,Julia Richter,Gesine Richter,Gesine Richter,Chris Lawerenz,Jules Kerssemakers,Christina Jaeger-Schmidt,Ingrid Scholz,Anke K. Bergmann,Christoph Borst,Birgit Burkhardt,Alexander Claviez,Martin Dreyling,Martin Dreyling,Sonja Eberth,Hermann Einsele,Norbert Frickhofen,Siegfried Haas,Martin-Leo Hansmann,Dennis Karsch,Michael Kneba,Jasmin Lisfeld,Luisa Mantovani-Löffler,Marius Rohde,German Ott,Christina Stadler,Peter Staib,Stephan Stilgenbauer,Lorenz Trümper,Thorsten Zenz,Dieter Kube,Ralf Küppers,Marc A. Weniger,Michael Hummel,Wolfram Klapper,Ulrike Kostezka,Dido Lenze,Peter Möller,Andreas Rosenwald,Monika Szczepanowski,Ole Ammerpohl,Sietse M. Aukema,Vera Binder,Jessica I. Hoell,Ellen Leich,Cristina López,Inga Nagel,Jordan Pischimariov,Philip Rosenstiel,Markus Schilhabel,Stefan Schreiber,Inga Vater,Rabea Wagener,Stephan H. Bernhart,Hans Binder,Gero Doose,Steve Hoffmann,Lydia Hopp,Helene Kretzmer,Markus Kreuz,David Langenberger,Markus Loeffler,Maciej Rosolowski,Matthias Schlesner,Peter F. Stadler,Stephanie Sungalee,Christian P. Kratz,Cornelis M. van Tilburg,Christof M. Kramm,Gudrun Fleischhack,Gudrun Fleischhack,Uta Dirksen,Stefan Rutkowski,Michael C. Frühwald,Katja von Hoff,Stephan Wolf,Thomas Klingebiel,Thomas Klingebiel,Ewa Koscielniak,Jan Koster,Adam C. Resnick,Jinghui Zhang,Yanling Liu,Xin Zhou,Angela J. Waanders,Danny A. Zwijnenburg,Pichai Raman,Ursula D. Weber,Paul A. Northcott,Kristian W. Pajtler,Marcel Kool,Rosario M. Piro,Jan O. Korbel,David T.W. Jones,Lukas Chavez,Stefan M. Pfister +185 more
TL;DR: The data suggest that 7–8% of the children in this cohort carry an unambiguous predisposing germline variant and that nearly 50% of paediatric neoplasms harbour a potentially druggable event, which is highly relevant for the design of future clinical trials.
Journal ArticleDOI
Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma
Tobias Otto,Sebastian Horn,Markus Brockmann,Ursula Eilers,Lars Schüttrumpf,Nikita Popov,Anna Marie Kenney,Johannes H. Schulte,Roderick L. Beijersbergen,Holger Christiansen,Bernd Berwanger,Martin Eilers +11 more
TL;DR: AURKA is identified as a gene that is required for the growth of MYCN-amplified neuroblastoma cells but largely dispensable for cells lacking amplified MYCN, and Aurora A has a critical function in regulating turnover of the N-Myc protein.
Journal ArticleDOI
Telomerase activation by genomic rearrangements in high-risk neuroblastoma
Martin Peifer,Falk Hertwig,Frederik Roels,Daniel Dreidax,Moritz Gartlgruber,Roopika Menon,Andrea Krämer,Justin L. Roncaioli,Frederik Sand,Johannes M. Heuckmann,Fakhera Ikram,Rene Schmidt,Sandra Ackermann,Anne Engesser,Yvonne Kahlert,Wenzel Vogel,Janine Altmüller,Peter Nürnberg,Jean Thierry-Mieg,Danielle Thierry-Mieg,Aruljothi Mariappan,Stefanie Heynck,Erika Mariotti,Kai-Oliver Henrich,Christian Gloeckner,Graziella Bosco,Ivo Leuschner,Michal R. Schweiger,Larissa Savelyeva,Simon C. Watkins,Chunxuan Shao,Emma Bell,Thomas Höfer,Viktor Achter,Ulrich Lang,Jessica Theissen,Ruth Volland,Maral Saadati,Angelika Eggert,Bram De Wilde,Frank Berthold,Zhiyu Peng,Chen Zhao,Leming Shi,Monika Ortmann,Reinhard Büttner,Sven Perner,Barbara Hero,Alexander Schramm,Johannes H. Schulte,Johannes H. Schulte,Carl Herrmann,Carl Herrmann,Roderick J. O’Sullivan,Frank Westermann,Roman K. Thomas,Matthias G. Fischer +56 more
TL;DR: It is shown that remodelling of the genomic context abrogates transcriptional silencing of TERT in high-risk neuroblastoma and places telomerase activation in the centre of transformation in a large fraction of these tumours.
Journal ArticleDOI
Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy
Johannes H. Schulte,Soyoung Lim,Alexander Schramm,Nicolaus Friedrichs,Jan Koster,Rogier Versteeg,Ingrid Øra,Kristian W. Pajtler,Ludger Klein-Hitpass,Steffi Kuhfittig-Kulle,Eric Metzger,Roland Schüle,Angelika Eggert,Reinhard Buettner,Jutta Kirfel +14 more
TL;DR: First evidence that a histone demethylase, LSD1, is involved in maintaining the undifferentiated, malignant phenotype of neuroblastoma cells is provided, showing that inhibition of LSD1 reprograms the transcriptome of neuro Blastoma cells and inhibits Neuroblastoma xenograft growth in vivo.
Journal ArticleDOI
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld,Derek A. Oldridge,Virginie Bernard,Jan Koster,Leo Colmet Daage,Sharon J. Diskin,Linda Schild,Nadia Bessoltane Bentahar,Angela Bellini,Mathieu Chicard,Eve Lapouble,Valérie Combaret,Patricia Legoix-Né,Jean Michon,Trevor J. Pugh,Lori S. Hart,JulieAnn Rader,Edward F. Attiyeh,Jun S. Wei,Shile Zhang,Arlene Naranjo,Julie M. Gastier-Foster,Michael D. Hogarty,Shahab Asgharzadeh,Malcolm A. Smith,Jaime M. Guidry Auvil,Thomas B.K. Watkins,Danny A. Zwijnenburg,Marli E. Ebus,Peter van Sluis,Anne Hakkert,Esther M. van Wezel,C. Ellen van der Schoot,Ellen M. Westerhout,Johannes H. Schulte,Godelieve A.M. Tytgat,M. Emmy M. Dolman,Isabelle Janoueix-Lerosey,Daniela S Gerhard,Huib N. Caron,Olivier Delattre,Javed Khan,Rogier Versteeg,Gudrun Schleiermacher,Jan J. Molenaar,John M. Maris +45 more
TL;DR: It is shown that RAS-MAPK pathway mutations may function as a biomarker for new therapeutic approaches to refractory disease and provide a rationale for genetic characterization of relapse neuroblastomas.